Pendleton Katherine E, Wang Karen, Echeverria Gloria V
Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, United States.
Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX, United States.
Front Cell Dev Biol. 2023 Sep 13;11:1254313. doi: 10.3389/fcell.2023.1254313. eCollection 2023.
Deregulation of tumor cell metabolism is widely recognized as a "hallmark of cancer." Many of the selective pressures encountered by tumor cells, such as exposure to anticancer therapies, navigation of the metastatic cascade, and communication with the tumor microenvironment, can elicit further rewiring of tumor cell metabolism. Furthermore, phenotypic plasticity has been recently appreciated as an emerging "hallmark of cancer." Mitochondria are dynamic organelles and central hubs of metabolism whose roles in cancers have been a major focus of numerous studies. Importantly, therapeutic approaches targeting mitochondria are being developed. Interestingly, both plastic (i.e., reversible) and permanent (i.e., stable) metabolic adaptations have been observed following exposure to anticancer therapeutics. Understanding the plastic or permanent nature of these mechanisms is of crucial importance for devising the initiation, duration, and sequential nature of metabolism-targeting therapies. In this review, we compare permanent and plastic mitochondrial mechanisms driving therapy resistance. We also discuss experimental models of therapy-induced metabolic adaptation, therapeutic implications for targeting permanent and plastic metabolic states, and clinical implications of metabolic adaptations. While the plasticity of metabolic adaptations can make effective therapeutic treatment challenging, understanding the mechanisms behind these plastic phenotypes may lead to promising clinical interventions that will ultimately lead to better overall care for cancer patients.
肿瘤细胞代谢失调被广泛认为是“癌症的标志”。肿瘤细胞所面临的许多选择性压力,如接触抗癌疗法、转移级联的导航以及与肿瘤微环境的通讯,都可能引发肿瘤细胞代谢的进一步重塑。此外,表型可塑性最近被视为一种新出现的“癌症标志”。线粒体是动态细胞器和代谢的核心枢纽,其在癌症中的作用一直是众多研究的主要焦点。重要的是,针对线粒体的治疗方法正在研发中。有趣的是,在接触抗癌治疗后,观察到了可塑性(即可逆性)和永久性(即稳定性)代谢适应。了解这些机制的可塑性或永久性本质对于设计代谢靶向治疗的起始、持续时间和顺序性质至关重要。在本综述中,我们比较了驱动治疗抗性的永久性和可塑性线粒体机制。我们还讨论了治疗诱导的代谢适应的实验模型、针对永久性和可塑性代谢状态的治疗意义以及代谢适应的临床意义。虽然代谢适应的可塑性可能使有效的治疗具有挑战性,但了解这些可塑性表型背后的机制可能会带来有前景的临床干预措施,最终为癌症患者带来更好的整体护理。